Trial Outcomes & Findings for Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain (NCT NCT02460692)
NCT ID: NCT02460692
Last Updated: 2023-09-28
Results Overview
The primary outcome is self-reported daily average numerical pain intensity during the past 24 hours. The numerical pain intensity is an 11-point pain intensity numerical rating scale (PI-NRS), where 0 equals no pain and 10 equals worst possible pain. The time frame includes baseline and weeks 1, 3, 5, 7, 8. Baseline is the pain tensity reported at the first day in the daily diary, before the first dose. The follow-up pain intensities (weeks 1, 3, 5, 7, 8) are the daily diary average pain intensities since the previously reported timepoint.
COMPLETED
PHASE2
131 participants
8 weeks
2023-09-28
Participant Flow
Participant milestones
| Measure |
Placebos
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-Tetrahydrocannabinol (THC)/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
During the titration period (weeks 0-4), participants undergo titration of vaporized medication from 4 puffs to 18 puffs, or oral medication from 5 mg qd to 10 mg tid per day. During the treatment period (weeks 5-8), participants are expected to consume the amount of study medication that they titrated themselves up to by the end of week 4.
|
Dronabinol
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
During the titration period (weeks 0-4), participants undergo titration of vaporized medication from 4 puffs to 18 puffs, or oral medication from 5 mg qd to 10 mg tid per day. During the treatment period (weeks 5-8), participants are expected to consume the amount of study medication that they titrated themselves up to by the end of week 4
|
Vaporized Cannabis 3.7% THC/5.6% CBD
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
During the titration period (weeks 0-4), participants undergo titration of vaporized medication from 4 puffs to 18 puffs, or oral medication from 5 mg qd to 10 mg tid per day. During the treatment period (weeks 5-8), participants are expected to consume the amount of study medication that they titrated themselves up to by the end of week 4
|
|---|---|---|---|
|
Overall Study
STARTED
|
44
|
43
|
44
|
|
Overall Study
COMPLETED
|
29
|
26
|
36
|
|
Overall Study
NOT COMPLETED
|
15
|
17
|
8
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain
Baseline characteristics by cohort
| Measure |
Placebos
n=44 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=43 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=44 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Total
n=131 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
38.8 years
STANDARD_DEVIATION 13.7 • n=99 Participants
|
48.6 years
STANDARD_DEVIATION 13 • n=107 Participants
|
47.4 years
STANDARD_DEVIATION 12.3 • n=206 Participants
|
44.9 years
STANDARD_DEVIATION 13.6 • n=7 Participants
|
|
Sex/Gender, Customized
Gender · Female
|
21 Participants
n=99 Participants
|
20 Participants
n=107 Participants
|
20 Participants
n=206 Participants
|
61 Participants
n=7 Participants
|
|
Sex/Gender, Customized
Gender · Male
|
23 Participants
n=99 Participants
|
21 Participants
n=107 Participants
|
23 Participants
n=206 Participants
|
67 Participants
n=7 Participants
|
|
Sex/Gender, Customized
Gender · Transgender (Female to Male)
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Sex/Gender, Customized
Gender · Transgender (Male to Female)
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
11 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
29 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
33 Participants
n=99 Participants
|
33 Participants
n=107 Participants
|
36 Participants
n=206 Participants
|
102 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
4 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
7 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
24 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
27 Participants
n=99 Participants
|
22 Participants
n=107 Participants
|
29 Participants
n=206 Participants
|
78 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
4 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
4 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
|
Education
|
14.2 Years
STANDARD_DEVIATION 2.2 • n=99 Participants
|
13.8 Years
STANDARD_DEVIATION 2.4 • n=107 Participants
|
14.6 Years
STANDARD_DEVIATION 2.6 • n=206 Participants
|
14.2 Years
STANDARD_DEVIATION 2.39 • n=7 Participants
|
PRIMARY outcome
Timeframe: 8 weeksPopulation: There are missing values.
The primary outcome is self-reported daily average numerical pain intensity during the past 24 hours. The numerical pain intensity is an 11-point pain intensity numerical rating scale (PI-NRS), where 0 equals no pain and 10 equals worst possible pain. The time frame includes baseline and weeks 1, 3, 5, 7, 8. Baseline is the pain tensity reported at the first day in the daily diary, before the first dose. The follow-up pain intensities (weeks 1, 3, 5, 7, 8) are the daily diary average pain intensities since the previously reported timepoint.
Outcome measures
| Measure |
Placebos
n=39 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=37 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=41 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Numerical Pain Intensity
Baseline
|
6.03 score on a scale
Standard Deviation 1.65
|
6.11 score on a scale
Standard Deviation 1.65
|
6.24 score on a scale
Standard Deviation 1.87
|
|
Numerical Pain Intensity
Week 1
|
5.97 score on a scale
Standard Deviation 2.01
|
5.80 score on a scale
Standard Deviation 1.62
|
5.64 score on a scale
Standard Deviation 1.98
|
|
Numerical Pain Intensity
Week 3
|
5.65 score on a scale
Standard Deviation 1.56
|
5.67 score on a scale
Standard Deviation 1.62
|
5.43 score on a scale
Standard Deviation 2.11
|
|
Numerical Pain Intensity
Week 5
|
5.47 score on a scale
Standard Deviation 1.77
|
4.89 score on a scale
Standard Deviation 1.88
|
4.82 score on a scale
Standard Deviation 2.29
|
|
Numerical Pain Intensity
Week 7
|
5.26 score on a scale
Standard Deviation 1.80
|
4.35 score on a scale
Standard Deviation 2.02
|
4.72 score on a scale
Standard Deviation 2.23
|
|
Numerical Pain Intensity
Week 8
|
5.22 score on a scale
Standard Deviation 1.92
|
4.19 score on a scale
Standard Deviation 2.02
|
4.45 score on a scale
Standard Deviation 2.11
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: There were some missing data
A Task Force was convened by the NIH Pain Consortium, with the goal of developing research standards for chronic low back pain. The results included recommendations for a repeated measures dataset in order to establish greater consistency in reporting in order to facilitate comparisons among studies. The repeated measure minimal dataset is based upon scores based upon the Patient-Reported Outcomes Measurement Information System ® (PROMIS). These items yield a classification of impacts on the lives of patients that range from 1 (least impact) to 42 (greatest impact).
Outcome measures
| Measure |
Placebos
n=44 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=42 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=44 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
Week 5
|
16.3 score on a scale
Standard Deviation 7.70
|
16.9 score on a scale
Standard Deviation 6.93
|
16.6 score on a scale
Standard Deviation 9.18
|
|
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
Week 7
|
16.2 score on a scale
Standard Deviation 7.42
|
15.1 score on a scale
Standard Deviation 7.17
|
16.1 score on a scale
Standard Deviation 9.88
|
|
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
Week 8
|
15.9 score on a scale
Standard Deviation 9.06
|
15.8 score on a scale
Standard Deviation 8.53
|
15.8 score on a scale
Standard Deviation 10.3
|
|
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
Baseline
|
21.6 score on a scale
Standard Deviation 7.29
|
22.5 score on a scale
Standard Deviation 6.46
|
23.1 score on a scale
Standard Deviation 7.03
|
|
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
Week 1
|
18.5 score on a scale
Standard Deviation 8.97
|
19.9 score on a scale
Standard Deviation 6.48
|
20.3 score on a scale
Standard Deviation 8.08
|
|
Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
Week 3
|
17.2 score on a scale
Standard Deviation 7.40
|
18.1 score on a scale
Standard Deviation 7.44
|
19.2 score on a scale
Standard Deviation 9.30
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: Some subjects dropped out before completing the study.
The Neuropathic Pain Scale (NPS) is an 11-point numerical scale consisting of 13 questions that ask ratings of various pain descriptors (including pain intensity, sharpness, burning, aching, cold, sensitivity, itching,unpleasantness, deep, and surface pain). The NPS is scored as the sum of these pain descriptors. Range of scores is from 0 to100. A higher score is a worse score.
Outcome measures
| Measure |
Placebos
n=44 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=43 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=44 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Neuropathic Pain Scale
Baseline
|
45.9 score on a scale
Standard Deviation 15.2
|
45.1 score on a scale
Standard Deviation 13.5
|
48.3 score on a scale
Standard Deviation 15.7
|
|
Neuropathic Pain Scale
Week 1
|
40.4 score on a scale
Standard Deviation 16.7
|
38.9 score on a scale
Standard Deviation 12.0
|
42.3 score on a scale
Standard Deviation 15.9
|
|
Neuropathic Pain Scale
Week 3
|
37.0 score on a scale
Standard Deviation 17.2
|
34.6 score on a scale
Standard Deviation 13.6
|
39.2 score on a scale
Standard Deviation 19.1
|
|
Neuropathic Pain Scale
Week 5
|
35.1 score on a scale
Standard Deviation 16.4
|
30.8 score on a scale
Standard Deviation 14.8
|
37.5 score on a scale
Standard Deviation 17.6
|
|
Neuropathic Pain Scale
Week 7
|
36.0 score on a scale
Standard Deviation 17.8
|
29.6 score on a scale
Standard Deviation 14.8
|
33.4 score on a scale
Standard Deviation 19.7
|
|
Neuropathic Pain Scale
Week 8
|
34.6 score on a scale
Standard Deviation 18.3
|
28.2 score on a scale
Standard Deviation 16.3
|
33.2 score on a scale
Standard Deviation 20.4
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: Some subjects dropped out before completing the study.
The Hopkins Verbal Learning Test provides information on the ability to learn and immediately recall verbal information across trials, as well at the ability to retain, reproduce, and recognize this information after a delay. A list of 12 words is presented to the subject over three trials. After each trial, the subject is to recall as many items as possible from the list in any desired order. A 20-minute delay follows the administration of the three trials, after which the subject is asked to recall the list. The ability to learn is represented by the number of correct words, with a score range of 0-36. A higher score indicates better performance.
Outcome measures
| Measure |
Placebos
n=44 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=42 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=44 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Hopkins Verbal Learning Test
Week 5
|
25.6 Number of correct words
Standard Deviation 3.84
|
24.0 Number of correct words
Standard Deviation 4.90
|
24.6 Number of correct words
Standard Deviation 4.55
|
|
Hopkins Verbal Learning Test
Week 7
|
24.3 Number of correct words
Standard Deviation 4.00
|
24.7 Number of correct words
Standard Deviation 4.78
|
23.8 Number of correct words
Standard Deviation 4.99
|
|
Hopkins Verbal Learning Test
Baseline
|
24.1 Number of correct words
Standard Deviation 5.24
|
23.7 Number of correct words
Standard Deviation 5.21
|
24.4 Number of correct words
Standard Deviation 4.90
|
|
Hopkins Verbal Learning Test
Week 1
|
24.0 Number of correct words
Standard Deviation 4.78
|
23.3 Number of correct words
Standard Deviation 4.44
|
24.0 Number of correct words
Standard Deviation 4.44
|
|
Hopkins Verbal Learning Test
Week 3
|
22.9 Number of correct words
Standard Deviation 3.74
|
23.6 Number of correct words
Standard Deviation 5.04
|
22.8 Number of correct words
Standard Deviation 4.08
|
|
Hopkins Verbal Learning Test
Week 8
|
24.0 Number of correct words
Standard Deviation 4.16
|
24.5 Number of correct words
Standard Deviation 4.68
|
24.8 Number of correct words
Standard Deviation 5.53
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: There were some missing data.
The Grooved Pegboard Test is a test of fine motor coordination and speed. Subjects are required to place 25 small metal pegs into holes on a 3" x 3" metal board. All pegs are alike and have a ridge on one side, which corresponds to a notch in each hole on the board. First the dominant hand is tested, and subjects are asked to place the pegs in the holes as fast as they can. This is then repeated with the non-dominant hand, and the total time for each hand is recorded. A higher score indicates worse performance.
Outcome measures
| Measure |
Placebos
n=44 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=42 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=43 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Grooved Pegboard Test - Dominant Hand
Baseline
|
63.7 seconds
Standard Deviation 10.6
|
73.4 seconds
Standard Deviation 21.1
|
69.1 seconds
Standard Deviation 14.4
|
|
Grooved Pegboard Test - Dominant Hand
Week 1
|
60.7 seconds
Standard Deviation 9.83
|
69.5 seconds
Standard Deviation 23.8
|
64.5 seconds
Standard Deviation 13.2
|
|
Grooved Pegboard Test - Dominant Hand
Week 3
|
61.1 seconds
Standard Deviation 14.1
|
63.1 seconds
Standard Deviation 10.9
|
64.1 seconds
Standard Deviation 11.2
|
|
Grooved Pegboard Test - Dominant Hand
Week 5
|
59.9 seconds
Standard Deviation 14.8
|
69.0 seconds
Standard Deviation 23.3
|
61.7 seconds
Standard Deviation 12.1
|
|
Grooved Pegboard Test - Dominant Hand
Week 7
|
59.7 seconds
Standard Deviation 13.6
|
68.7 seconds
Standard Deviation 24.9
|
62.5 seconds
Standard Deviation 13.3
|
|
Grooved Pegboard Test - Dominant Hand
Week 8
|
60.8 seconds
Standard Deviation 18.5
|
69.2 seconds
Standard Deviation 27.6
|
61.7 seconds
Standard Deviation 12.7
|
SECONDARY outcome
Timeframe: 8 weeksThe Digit Symbol test measures concentration, psychomotor speed, and graphomotor abilities. This pen and paper test involves having subjects substitute a series of symbols with numbers as quickly and accurately as possible during a 120 second period. The results are expressed as the number of correct substitutions with a score range of 0-133. A higher number indicates better performance.
Outcome measures
| Measure |
Placebos
n=44 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=43 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=42 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Wechsler Adult Intelligence Scale-III Digit Symbol Test
Week 8
|
84.8 number of correct symbols
Standard Deviation 22.6
|
79.3 number of correct symbols
Standard Deviation 21.9
|
87.3 number of correct symbols
Standard Deviation 18.6
|
|
Wechsler Adult Intelligence Scale-III Digit Symbol Test
Baseline
|
80.3 number of correct symbols
Standard Deviation 14.9
|
69.6 number of correct symbols
Standard Deviation 17.2
|
72.2 number of correct symbols
Standard Deviation 15.6
|
|
Wechsler Adult Intelligence Scale-III Digit Symbol Test
Week 1
|
84.8 number of correct symbols
Standard Deviation 17.2
|
73.5 number of correct symbols
Standard Deviation 19.3
|
78.3 number of correct symbols
Standard Deviation 16.7
|
|
Wechsler Adult Intelligence Scale-III Digit Symbol Test
Week 3
|
88.9 number of correct symbols
Standard Deviation 17.5
|
75.6 number of correct symbols
Standard Deviation 18.2
|
77.6 number of correct symbols
Standard Deviation 19.7
|
|
Wechsler Adult Intelligence Scale-III Digit Symbol Test
Week 5
|
90.0 number of correct symbols
Standard Deviation 19.7
|
79.2 number of correct symbols
Standard Deviation 20.9
|
83.1 number of correct symbols
Standard Deviation 18.8
|
|
Wechsler Adult Intelligence Scale-III Digit Symbol Test
Week 7
|
88.4 number of correct symbols
Standard Deviation 20.9
|
79.8 number of correct symbols
Standard Deviation 19.8
|
81.0 number of correct symbols
Standard Deviation 21.3
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: There were some missing data.
This questionnaire contains 65 words/statements that describe feelings people have. The questionnaire requires the patient to indicate for each word or statement how he or she has been feeling in the past week. There are 6 subscales: tension-anxiety (9 items, score range: 0-36), depression (15 items, range 0-60), anger-hostility (12 items, range 0-48), vigor-activity (8 items, range 0-32), fatigue (7 items, range 0-28), confusion-bewilderment (7 items, range 0-28). The total mood disturbance (TMD) is calculated by adding the scores for tension-anxiety, depression, anger-hostility, fatigue and confusion-bewilderment and then subtracting the score for vigor-activity. The TMD is reported and has a score range of -32 to 200. A higher score indicates worse symptoms.
Outcome measures
| Measure |
Placebos
n=44 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=42 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=44 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Profile of Mood States
Baseline
|
57.3 score on a scale
Standard Deviation 32.0
|
53.8 score on a scale
Standard Deviation 31.5
|
53.2 score on a scale
Standard Deviation 30.6
|
|
Profile of Mood States
Week 1
|
51.5 score on a scale
Standard Deviation 36.9
|
46.2 score on a scale
Standard Deviation 23.6
|
41.5 score on a scale
Standard Deviation 22.2
|
|
Profile of Mood States
Week 3
|
48.6 score on a scale
Standard Deviation 30.6
|
42.9 score on a scale
Standard Deviation 27.4
|
38.8 score on a scale
Standard Deviation 23.3
|
|
Profile of Mood States
Week 5
|
46.3 score on a scale
Standard Deviation 27.2
|
40.0 score on a scale
Standard Deviation 22.7
|
38.8 score on a scale
Standard Deviation 22.0
|
|
Profile of Mood States
Week 7
|
45.5 score on a scale
Standard Deviation 27.3
|
37.7 score on a scale
Standard Deviation 23.7
|
44.2 score on a scale
Standard Deviation 29.2
|
|
Profile of Mood States
Week 8
|
42.5 score on a scale
Standard Deviation 30.9
|
41.0 score on a scale
Standard Deviation 28.5
|
39.7 score on a scale
Standard Deviation 26.6
|
SECONDARY outcome
Timeframe: 8 weeksThe Beck Depression Inventory is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Range of scores is from 0 to 63. A higher score is a worse score.
Outcome measures
| Measure |
Placebos
n=41 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=42 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=44 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Beck Depression Inventory II
Baseline
|
8.05 score on a scale
Standard Deviation 7.99
|
7.81 score on a scale
Standard Deviation 8.26
|
7.84 score on a scale
Standard Deviation 8.14
|
|
Beck Depression Inventory II
Week 1
|
7.68 score on a scale
Standard Deviation 8.70
|
5.61 score on a scale
Standard Deviation 5.00
|
5.32 score on a scale
Standard Deviation 6.05
|
|
Beck Depression Inventory II
Week 3
|
5.76 score on a scale
Standard Deviation 6.59
|
5.26 score on a scale
Standard Deviation 6.81
|
5.59 score on a scale
Standard Deviation 7.24
|
|
Beck Depression Inventory II
Week 5
|
5.32 score on a scale
Standard Deviation 7.07
|
5.52 score on a scale
Standard Deviation 6.28
|
6.25 score on a scale
Standard Deviation 8.52
|
|
Beck Depression Inventory II
Week 7
|
5.50 score on a scale
Standard Deviation 7.63
|
4.36 score on a scale
Standard Deviation 6.49
|
6.09 score on a scale
Standard Deviation 8.63
|
|
Beck Depression Inventory II
Week 8
|
5.32 score on a scale
Standard Deviation 7.39
|
5.25 score on a scale
Standard Deviation 8.11
|
6.06 score on a scale
Standard Deviation 9.62
|
SECONDARY outcome
Timeframe: 6 hoursPopulation: There are some missing values
Visual Analogue Scale (VAS) ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. A good drug effect is presented. Range of scores is from 0 to 100. A higher score is a worse score.
Outcome measures
| Measure |
Placebos
n=8 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=13 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=21 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Locally Developed Psychoactive Effect Scale - Good Drug Effect
After dose 1 hour
|
14.2 score on a scale
Standard Deviation 24.4
|
19.1 score on a scale
Standard Deviation 34.3
|
58.8 score on a scale
Standard Deviation 32.5
|
|
Locally Developed Psychoactive Effect Scale - Good Drug Effect
After dose 2 hours
|
14.0 score on a scale
Standard Deviation 23.8
|
33.5 score on a scale
Standard Deviation 38.5
|
45.7 score on a scale
Standard Deviation 31.7
|
|
Locally Developed Psychoactive Effect Scale - Good Drug Effect
After dose 3 hours
|
5.88 score on a scale
Standard Deviation 14.3
|
33.2 score on a scale
Standard Deviation 44.1
|
27.5 score on a scale
Standard Deviation 29.5
|
|
Locally Developed Psychoactive Effect Scale - Good Drug Effect
After dose 4 hours
|
7.43 score on a scale
Standard Deviation 15.9
|
36.3 score on a scale
Standard Deviation 42.8
|
37.0 score on a scale
Standard Deviation 37.5
|
|
Locally Developed Psychoactive Effect Scale - Good Drug Effect
After dose 5 hours
|
11.6 score on a scale
Standard Deviation 28.5
|
29.7 score on a scale
Standard Deviation 41.9
|
44.4 score on a scale
Standard Deviation 34.3
|
|
Locally Developed Psychoactive Effect Scale - Good Drug Effect
After dose 6 hours
|
10.7 score on a scale
Standard Deviation 27.0
|
32.4 score on a scale
Standard Deviation 41.4
|
40.4 score on a scale
Standard Deviation 35.9
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: There were missing values.
The Marijuana subscale (M-scale) of the Addiction Research Center Inventory consists of 12 true or false questions corresponding to symptoms of cannabis intoxication; the minimum and maximum scores are 0 and 12 respectively. A higher score indicates a worse score. The questions were rephrased to evaluate the experience from the past week rather than an acute response to cannabis.
Outcome measures
| Measure |
Placebos
n=37 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=36 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=42 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Marijuana Subscale (M-scale) of the Addiction Research Center Inventory
Week 1
|
1.59 score on a scale
Standard Deviation 2.02
|
1.81 score on a scale
Standard Deviation 1.72
|
2.31 score on a scale
Standard Deviation 2.28
|
|
Marijuana Subscale (M-scale) of the Addiction Research Center Inventory
Week 3
|
1.63 score on a scale
Standard Deviation 2.11
|
2.47 score on a scale
Standard Deviation 2.21
|
2.33 score on a scale
Standard Deviation 1.91
|
|
Marijuana Subscale (M-scale) of the Addiction Research Center Inventory
Week 5
|
1.31 score on a scale
Standard Deviation 2.19
|
2.93 score on a scale
Standard Deviation 2.51
|
2.67 score on a scale
Standard Deviation 2.41
|
|
Marijuana Subscale (M-scale) of the Addiction Research Center Inventory
Week 7
|
1.61 score on a scale
Standard Deviation 2.41
|
2.46 score on a scale
Standard Deviation 2.38
|
2.80 score on a scale
Standard Deviation 2.47
|
|
Marijuana Subscale (M-scale) of the Addiction Research Center Inventory
Week 8
|
1.11 score on a scale
Standard Deviation 1.95
|
2.29 score on a scale
Standard Deviation 2.34
|
2.31 score on a scale
Standard Deviation 2.36
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: There were missing values
Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.
Outcome measures
| Measure |
Placebos
n=37 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=33 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=37 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Cold Pressor Test - Pain Sensitivity
Pain sensitivity Baseline
|
20.0 seconds
Standard Deviation 26.5
|
18.3 seconds
Standard Deviation 21.8
|
26.3 seconds
Standard Deviation 30.1
|
|
Cold Pressor Test - Pain Sensitivity
Week 1
|
29.4 seconds
Standard Deviation 36.9
|
23.0 seconds
Standard Deviation 31.6
|
20.5 seconds
Standard Deviation 29.3
|
|
Cold Pressor Test - Pain Sensitivity
Week 3
|
21.9 seconds
Standard Deviation 27.5
|
18.8 seconds
Standard Deviation 22.6
|
21.0 seconds
Standard Deviation 23.5
|
|
Cold Pressor Test - Pain Sensitivity
Week 5
|
20.9 seconds
Standard Deviation 28.4
|
20.4 seconds
Standard Deviation 24.8
|
24.7 seconds
Standard Deviation 28.8
|
|
Cold Pressor Test - Pain Sensitivity
Week 7
|
20.4 seconds
Standard Deviation 26.6
|
21.5 seconds
Standard Deviation 25.7
|
20.9 seconds
Standard Deviation 24.7
|
|
Cold Pressor Test - Pain Sensitivity
Week 8
|
21.1 seconds
Standard Deviation 24.3
|
15.8 seconds
Standard Deviation 11.0
|
23.9 seconds
Standard Deviation 30.6
|
SECONDARY outcome
Timeframe: Week 8 and Week 10Population: Some subjects dropped out before completing the study.
The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). Range of scores for withdrawal intensity is from 0 to 190. A higher score is a worse score.
Outcome measures
| Measure |
Placebos
n=28 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=27 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=35 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Cannabis Withdrawal Scale - Withdrawal Intensity
Week 8
|
13.5 score on a scale
Standard Deviation 23.7
|
6.12 score on a scale
Standard Deviation 8.98
|
12.4 score on a scale
Standard Deviation 25.2
|
|
Cannabis Withdrawal Scale - Withdrawal Intensity
Week 10
|
12.7 score on a scale
Standard Deviation 25.1
|
6.32 score on a scale
Standard Deviation 10.2
|
9.97 score on a scale
Standard Deviation 20.1
|
SECONDARY outcome
Timeframe: 270 minutesPopulation: There are some missing values
Lane Tracking: This task requires subjects to drive down a straight 2-lane road, maintain a constant speed of 55 mph, maintain appropriate lane position, and respond to divided attention tasks in the upper corners of the screen. The primary outcome is standard deviation of lateral deviation (swerving) with a score range of 0.51 - 3.24. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy.
Outcome measures
| Measure |
Placebos
n=5 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=11 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=16 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Driving Simulation (Lane Tracking)
Pre Dose
|
0.75 score on a scale
Standard Deviation 0.18
|
1.28 score on a scale
Standard Deviation 0.65
|
1.14 score on a scale
Standard Deviation 0.41
|
|
Driving Simulation (Lane Tracking)
After First Dose 30 minutes
|
1.18 score on a scale
Standard Deviation 0.43
|
1.41 score on a scale
Standard Deviation 0.61
|
1.12 score on a scale
Standard Deviation 0.32
|
|
Driving Simulation (Lane Tracking)
After First Dose 100 minutes
|
1.12 score on a scale
Standard Deviation 0.57
|
1.78 score on a scale
Standard Deviation 0.87
|
1.21 score on a scale
Standard Deviation 0.35
|
|
Driving Simulation (Lane Tracking)
After First Dose 230 minutes
|
1.31 score on a scale
Standard Deviation 0.57
|
1.51 score on a scale
Standard Deviation 0.76
|
1.11 score on a scale
Standard Deviation 0.25
|
|
Driving Simulation (Lane Tracking)
After Second Dose 30 minutes
|
1.13 score on a scale
Standard Deviation 0.47
|
1.65 score on a scale
Standard Deviation 0.79
|
1.24 score on a scale
Standard Deviation 0.39
|
SECONDARY outcome
Timeframe: 270 minutesCar Following: This simulation examines the participant's ability to closely match the speed of an automobile in front of them. Participants are to follow a lead vehicle at a safe and constant distance. The primary outcome is coherence between the participant and lead cars (a general correlation \[0-1\] of the participant's ability to accurately track the speed variations of the lead car. A higher score indicates worse performance. The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy.
Outcome measures
| Measure |
Placebos
n=5 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=11 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=16 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Driving Simulation (Car Following)
Pre Dose
|
0.70 score on a scale
Standard Deviation 0.17
|
0.62 score on a scale
Standard Deviation 0.20
|
0.49 score on a scale
Standard Deviation 0.29
|
|
Driving Simulation (Car Following)
After First Dose 30 minutes
|
0.75 score on a scale
Standard Deviation 0.13
|
0.71 score on a scale
Standard Deviation 0.20
|
0.61 score on a scale
Standard Deviation 0.23
|
|
Driving Simulation (Car Following)
After First Dose 100 minutes
|
0.59 score on a scale
Standard Deviation 0.33
|
0.68 score on a scale
Standard Deviation 0.20
|
0.56 score on a scale
Standard Deviation 0.22
|
|
Driving Simulation (Car Following)
After First Dose 230 minutes
|
0.72 score on a scale
Standard Deviation 0.24
|
0.60 score on a scale
Standard Deviation 0.27
|
0.62 score on a scale
Standard Deviation 0.25
|
|
Driving Simulation (Car Following)
After Second Dose 30 minutes
|
0.74 score on a scale
Standard Deviation 0.19
|
0.68 score on a scale
Standard Deviation 0.26
|
0.60 score on a scale
Standard Deviation 0.22
|
SECONDARY outcome
Timeframe: 6 hoursPopulation: There are some missing values
A total of 15 separate VAS ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel \_\_\_after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry. This is a substudy. Drug "high" will be presented. Range of scores is from 0 to 100. A higher score is a worse score.
Outcome measures
| Measure |
Placebos
n=8 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=13 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=21 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Locally Developed Psychoactive Effect Scale - High
After dose 1 hour
|
5.38 score on a scale
Standard Deviation 12.2
|
14.9 score on a scale
Standard Deviation 31.5
|
49.8 score on a scale
Standard Deviation 30.7
|
|
Locally Developed Psychoactive Effect Scale - High
After dose 2 hours
|
5.75 score on a scale
Standard Deviation 14.7
|
25.8 score on a scale
Standard Deviation 38.1
|
36.7 score on a scale
Standard Deviation 27.1
|
|
Locally Developed Psychoactive Effect Scale - High
After dose 3 hours
|
5.56 score on a scale
Standard Deviation 13.2
|
31.8 score on a scale
Standard Deviation 40.5
|
20.5 score on a scale
Standard Deviation 22.5
|
|
Locally Developed Psychoactive Effect Scale - High
After dose 4 hours
|
4.00 score on a scale
Standard Deviation 7.00
|
28.6 score on a scale
Standard Deviation 32.5
|
29.5 score on a scale
Standard Deviation 32.8
|
|
Locally Developed Psychoactive Effect Scale - High
After dose 5 hours
|
1.75 score on a scale
Standard Deviation 1.83
|
21.5 score on a scale
Standard Deviation 36.9
|
43.9 score on a scale
Standard Deviation 32.8
|
|
Locally Developed Psychoactive Effect Scale - High
After dose 6 hours
|
1.71 score on a scale
Standard Deviation 3.40
|
24.8 score on a scale
Standard Deviation 38.7
|
31.7 score on a scale
Standard Deviation 30.3
|
SECONDARY outcome
Timeframe: Week 8, Week 10Population: Some subjects dropped out before completing the study.
The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). The outcome is measured during the tapering period (weeks 8 and 10), at which patients slowly withdrew from medication over two weeks. Range of scores for the negative impact of withdrawal is from 0 to 190. A higher score is a worse score.
Outcome measures
| Measure |
Placebos
n=28 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=27 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=35 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Cannabis Withdrawal Scale - Negative Impact of Withdrawal
Week 8
|
8.42 score on a scale
Standard Deviation 22.9
|
3.42 score on a scale
Standard Deviation 7.22
|
10.3 score on a scale
Standard Deviation 24.6
|
|
Cannabis Withdrawal Scale - Negative Impact of Withdrawal
Week 10
|
8.18 score on a scale
Standard Deviation 24.0
|
2.32 score on a scale
Standard Deviation 8.63
|
4.31 score on a scale
Standard Deviation 10.5
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: There were some missing values
Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath.
Outcome measures
| Measure |
Placebos
n=37 Participants
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=33 Participants
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=37 Participants
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Cold Pressor Test - Pain Tolerance
Baseline
|
47.2 seconds
Standard Deviation 42.0
|
40.6 seconds
Standard Deviation 34.1
|
58.3 seconds
Standard Deviation 46.0
|
|
Cold Pressor Test - Pain Tolerance
Week 1
|
50.5 seconds
Standard Deviation 40.4
|
44.8 seconds
Standard Deviation 46.9
|
60.9 seconds
Standard Deviation 48.8
|
|
Cold Pressor Test - Pain Tolerance
Week 3
|
46.2 seconds
Standard Deviation 38.0
|
40.0 seconds
Standard Deviation 34.3
|
64.3 seconds
Standard Deviation 49.3
|
|
Cold Pressor Test - Pain Tolerance
Week 5
|
41.4 seconds
Standard Deviation 39.5
|
43.6 seconds
Standard Deviation 41.5
|
60.7 seconds
Standard Deviation 45.9
|
|
Cold Pressor Test - Pain Tolerance
Week 7
|
61.7 seconds
Standard Deviation 53.8
|
44.2 seconds
Standard Deviation 40.4
|
54.7 seconds
Standard Deviation 42.9
|
|
Cold Pressor Test - Pain Tolerance
Week 8
|
37.9 seconds
Standard Deviation 35.0
|
37.5 seconds
Standard Deviation 32.4
|
62.3 seconds
Standard Deviation 45.8
|
Adverse Events
Placebos
Dronabinol
Vaporized Cannabis 3.7% THC/5.6% CBD
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Placebos
n=44 participants at risk
The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
Placebos: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Dronabinol
n=43 participants at risk
A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
dronabinol: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
Vaporized Cannabis 3.7% THC/5.6% CBD
n=44 participants at risk
The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
Vaporized Cannabis 3.7% THC/5.6% CBD: Administration of vaporized cannabis plus either dronabinol or placebo pill
|
|---|---|---|---|
|
Gastrointestinal disorders
Nausea
|
18.2%
8/44 • Number of events 10 • 10 weeks
|
25.6%
11/43 • Number of events 12 • 10 weeks
|
25.0%
11/44 • Number of events 14 • 10 weeks
|
|
Nervous system disorders
Confusion
|
18.2%
8/44 • Number of events 10 • 10 weeks
|
23.3%
10/43 • Number of events 14 • 10 weeks
|
15.9%
7/44 • Number of events 9 • 10 weeks
|
|
Nervous system disorders
Lethargy
|
43.2%
19/44 • Number of events 25 • 10 weeks
|
37.2%
16/43 • Number of events 32 • 10 weeks
|
52.3%
23/44 • Number of events 37 • 10 weeks
|
|
Nervous system disorders
Dry Mouth
|
18.2%
8/44 • Number of events 9 • 10 weeks
|
44.2%
19/43 • Number of events 26 • 10 weeks
|
27.3%
12/44 • Number of events 17 • 10 weeks
|
|
Nervous system disorders
Headache
|
31.8%
14/44 • Number of events 18 • 10 weeks
|
27.9%
12/43 • Number of events 12 • 10 weeks
|
31.8%
14/44 • Number of events 21 • 10 weeks
|
|
Nervous system disorders
Abnormal cognition
|
6.8%
3/44 • Number of events 3 • 10 weeks
|
23.3%
10/43 • Number of events 12 • 10 weeks
|
22.7%
10/44 • Number of events 13 • 10 weeks
|
|
Nervous system disorders
Depression
|
20.5%
9/44 • Number of events 10 • 10 weeks
|
18.6%
8/43 • Number of events 10 • 10 weeks
|
13.6%
6/44 • Number of events 9 • 10 weeks
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
9.1%
4/44 • Number of events 6 • 10 weeks
|
18.6%
8/43 • Number of events 9 • 10 weeks
|
25.0%
11/44 • Number of events 14 • 10 weeks
|
|
Nervous system disorders
Vomiting
|
4.5%
2/44 • Number of events 3 • 10 weeks
|
9.3%
4/43 • Number of events 4 • 10 weeks
|
13.6%
6/44 • Number of events 6 • 10 weeks
|
|
Nervous system disorders
Dizzy
|
15.9%
7/44 • Number of events 8 • 10 weeks
|
16.3%
7/43 • Number of events 8 • 10 weeks
|
20.5%
9/44 • Number of events 9 • 10 weeks
|
|
Nervous system disorders
Emotional Changes
|
22.7%
10/44 • Number of events 10 • 10 weeks
|
20.9%
9/43 • Number of events 13 • 10 weeks
|
31.8%
14/44 • Number of events 15 • 10 weeks
|
|
Nervous system disorders
Sleeping Problems
|
0.00%
0/44 • 10 weeks
|
2.3%
1/43 • Number of events 1 • 10 weeks
|
0.00%
0/44 • 10 weeks
|
|
Nervous system disorders
Paranoia
|
4.5%
2/44 • Number of events 4 • 10 weeks
|
14.0%
6/43 • Number of events 7 • 10 weeks
|
4.5%
2/44 • Number of events 3 • 10 weeks
|
|
General disorders
Stomach Pain
|
4.5%
2/44 • Number of events 2 • 10 weeks
|
14.0%
6/43 • Number of events 8 • 10 weeks
|
11.4%
5/44 • Number of events 6 • 10 weeks
|
|
Nervous system disorders
Abnormal Coordination
|
13.6%
6/44 • Number of events 6 • 10 weeks
|
23.3%
10/43 • Number of events 15 • 10 weeks
|
18.2%
8/44 • Number of events 10 • 10 weeks
|
|
Nervous system disorders
Anxiety
|
18.2%
8/44 • Number of events 8 • 10 weeks
|
16.3%
7/43 • Number of events 10 • 10 weeks
|
18.2%
8/44 • Number of events 10 • 10 weeks
|
|
Nervous system disorders
Back/Flank Paresthesia
|
9.1%
4/44 • Number of events 4 • 10 weeks
|
14.0%
6/43 • Number of events 8 • 10 weeks
|
13.6%
6/44 • Number of events 7 • 10 weeks
|
|
Nervous system disorders
Abnormal Dreams
|
11.4%
5/44 • Number of events 7 • 10 weeks
|
7.0%
3/43 • Number of events 5 • 10 weeks
|
18.2%
8/44 • Number of events 13 • 10 weeks
|
|
Nervous system disorders
Back/Flank Numbness
|
13.6%
6/44 • Number of events 6 • 10 weeks
|
2.3%
1/43 • Number of events 1 • 10 weeks
|
6.8%
3/44 • Number of events 3 • 10 weeks
|
|
Nervous system disorders
Abnormal Balance
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
4.7%
2/43 • Number of events 2 • 10 weeks
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
|
Nervous system disorders
Orthostatic Hypotension
|
6.8%
3/44 • Number of events 4 • 10 weeks
|
2.3%
1/43 • Number of events 2 • 10 weeks
|
4.5%
2/44 • Number of events 2 • 10 weeks
|
|
Nervous system disorders
Abnormal heart rate
|
4.5%
2/44 • Number of events 4 • 10 weeks
|
4.7%
2/43 • Number of events 2 • 10 weeks
|
9.1%
4/44 • Number of events 4 • 10 weeks
|
|
Nervous system disorders
Vision Alteration
|
4.5%
2/44 • Number of events 2 • 10 weeks
|
7.0%
3/43 • Number of events 3 • 10 weeks
|
4.5%
2/44 • Number of events 2 • 10 weeks
|
|
Nervous system disorders
Blood pressure decreased
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
4.7%
2/43 • Number of events 3 • 10 weeks
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
|
Nervous system disorders
Abdomen/Groin/Pelvis Pain
|
4.5%
2/44 • Number of events 2 • 10 weeks
|
4.7%
2/43 • Number of events 2 • 10 weeks
|
4.5%
2/44 • Number of events 2 • 10 weeks
|
|
Nervous system disorders
Blood pressure increased
|
0.00%
0/44 • 10 weeks
|
2.3%
1/43 • Number of events 1 • 10 weeks
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
|
General disorders
Face/Jaw/Lips dry
|
0.00%
0/44 • 10 weeks
|
2.3%
1/43 • Number of events 1 • 10 weeks
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
|
Nervous system disorders
Generalized/Multiple site numbness
|
0.00%
0/44 • 10 weeks
|
4.7%
2/43 • Number of events 2 • 10 weeks
|
0.00%
0/44 • 10 weeks
|
|
Nervous system disorders
Behavior changes
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
2.3%
1/43 • Number of events 1 • 10 weeks
|
0.00%
0/44 • 10 weeks
|
|
Nervous system disorders
Bronchial washing nausea
|
0.00%
0/44 • 10 weeks
|
2.3%
1/43 • Number of events 1 • 10 weeks
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
|
Nervous system disorders
Cronic bronchitis
|
0.00%
0/44 • 10 weeks
|
2.3%
1/43 • Number of events 1 • 10 weeks
|
0.00%
0/44 • 10 weeks
|
|
Nervous system disorders
Sexual drive alteration
|
2.3%
1/44 • Number of events 1 • 10 weeks
|
2.3%
1/43 • Number of events 1 • 10 weeks
|
0.00%
0/44 • 10 weeks
|
Additional Information
Thomas D. Marcotte, PhD
University of California, San Diego
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place